Terumo Co. (OTCMKTS:TRUMY – Get Rating) – Research analysts at Jefferies Financial Group upped their FY2024 earnings per share estimates for shares of Terumo in a research note issued to investors on Tuesday, May 31st. Jefferies Financial Group analyst S. Barker now forecasts that the company will post earnings of $1.57 per share for the year, up from their prior estimate of $1.46. Jefferies Financial Group also issued estimates for Terumo’s FY2025 earnings at $1.73 EPS and FY2026 earnings at $1.86 EPS.
Separately, Zacks Investment Research upgraded Terumo from a “sell” rating to a “hold” rating in a report on Wednesday, April 13th.
Terumo Company Profile (Get Rating)
Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts.
- Get a free copy of the StockNews.com research report on Terumo (TRUMY)
- Alibaba Group: Rallying on Fundamentals & Improved Macro Backdrop
- Investing in Chewy Will Require More Than One Earnings Report
- JFrog Stock is Ready to Leap
- Hormel Foods Sends A Message To The Market
- PVH Corp. Looks Sharp For A Major Reversal
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.